Adenocarcinoma Prostate

Adenocarcinoma of the prostate is the most common form of prostate cancer, accounting for roughly 95 percent of all cases diagnosed in men. It develops in the glandular cells of the prostate, a walnut-sized organ located beneath the bladder that produces seminal fluid. In Ireland, prostate cancer is the most frequently diagnosed cancer in men, and the overwhelming majority of those diagnoses are adenocarcinomas. Although the disease can be serious, it often grows slowly, and with earlier detection and modern treatment, the outlook for many men is excellent. Understanding what adenocarcinoma of the prostate is, how it is detected, and how it is treated can help men and their families navigate the journey from diagnosis to recovery with confidence.

Understanding Prostate Adenocarcinoma

Prostate adenocarcinoma begins when the epithelial cells lining the prostate's glands multiply in an uncontrolled way. Over time, these abnormal cells can form a tumour within the gland and, in some cases, spread to surrounding tissues, lymph nodes, or bones. Most prostate adenocarcinomas are of the acinar type, meaning they originate in the acini, the small sacs that produce prostate fluid. Because the early stages of the disease often produce no symptoms at all, many men are diagnosed only after routine testing. When symptoms do appear, they may include difficulty urinating, a weak or interrupted urine flow, blood in the urine or semen, and persistent discomfort in the pelvic area. Men experiencing any of these symptoms should consult their GP promptly rather than waiting for them to resolve on their own.

Early Detection and Diagnosis

Early detection is one of the most important factors in treating prostate adenocarcinoma successfully. The two most common screening tools are the prostate-specific antigen (PSA) blood test and the digital rectal examination (DRE). If either test raises concern, a doctor will usually refer the patient to a urologist for further investigation, which may include multiparametric MRI and a transrectal or transperineal biopsy. Biopsy tissue is examined under a microscope and assigned a Gleason score, which grades how abnormal the cells appear and helps predict how aggressively the cancer is likely to behave. This information, combined with the PSA level and the clinical stage of the tumour, shapes the treatment plan and gives the care team a clear picture of the man's prognosis.

Treatment Options and Outlook

Treatment for prostate adenocarcinoma depends on the stage and grade of the tumour, the man's age, and his general health. For slow-growing, low-risk cancers, active surveillance — regular monitoring with PSA tests and repeat biopsies — may be recommended to avoid unnecessary treatment and its side effects. Where treatment is needed, options include surgery to remove the prostate, external beam radiotherapy or brachytherapy, and hormone therapy that reduces the level of testosterone fuelling the cancer's growth. In advanced cases, chemotherapy and newer targeted or immunotherapy agents may be used. Each option carries its own benefits and potential side effects, such as urinary incontinence and erectile dysfunction, and men should discuss these in detail with their oncology team before making a decision.

Support and the Road Ahead

Being diagnosed with prostate adenocarcinoma can be a frightening experience, but men in Ireland have access to a wide range of supports, including specialist urology and oncology services, patient advocacy groups, and cancer support centres offering counselling and practical advice. Survival rates for prostate cancer have improved steadily over recent decades, and many men live long, full lives after treatment. Regular follow-up care remains important, however, because the cancer can sometimes return years after treatment. Men who notice urinary symptoms, or who have a family history of prostate or breast cancer, should speak with their GP about their individual risk and the appropriate screening schedule for their situation.